327 related articles for article (PubMed ID: 19812490)
1. Acute graft-versus-host disease: new treatment strategies.
Paczesny S; Choi SW; Ferrara JL
Curr Opin Hematol; 2009 Nov; 16(6):427-36. PubMed ID: 19812490
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
[TBL] [Abstract][Full Text] [Related]
4. Treatment of chronic graft-versus-host disease in 2011.
Inamoto Y; Flowers ME
Curr Opin Hematol; 2011 Nov; 18(6):414-20. PubMed ID: 21912257
[TBL] [Abstract][Full Text] [Related]
5. The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease.
Kumar S; Leigh ND; Cao X
Front Immunol; 2018; 9():3003. PubMed ID: 30627129
[TBL] [Abstract][Full Text] [Related]
6. Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial.
Kitko CL; Braun T; Couriel DR; Choi SW; Connelly J; Hoffmann S; Goldstein S; Magenau J; Pawarode A; Reddy P; Schuler C; Yanik GA; Ferrara JL; Levine JE
Biol Blood Marrow Transplant; 2016 May; 22(5):862-8. PubMed ID: 26551636
[TBL] [Abstract][Full Text] [Related]
7. Acute graft-versus-host disease: are we close to bringing the bench to the bedside?
Sung AD; Chao NJ
Best Pract Res Clin Haematol; 2013 Sep; 26(3):285-92. PubMed ID: 24309532
[TBL] [Abstract][Full Text] [Related]
8. New developments in allotransplant immunology.
Barrett AJ; Rezvani K; Solomon S; Dickinson AM; Wang XN; Stark G; Cullup H; Jarvis M; Middleton PG; Chao N
Hematology Am Soc Hematol Educ Program; 2003; ():350-71. PubMed ID: 14633790
[TBL] [Abstract][Full Text] [Related]
9. Current and novel therapies in acute GVHD.
Ho VT; Cutler C
Best Pract Res Clin Haematol; 2008 Jun; 21(2):223-37. PubMed ID: 18503988
[TBL] [Abstract][Full Text] [Related]
10. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
Chang YJ; Zhao XY; Huang XJ
Front Immunol; 2018; 9():3041. PubMed ID: 30619371
[TBL] [Abstract][Full Text] [Related]
11. Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation.
Toubai T; Guoqing H; Rossi C; Mathewson N; Oravecz-Wilson K; Cummings E; Wu J; Sun Y; Choi S; Reddy P
Oncoimmunology; 2015 Jul; 4(7):e1016699. PubMed ID: 26140241
[TBL] [Abstract][Full Text] [Related]
12. Regulation of the Immune Balance During Allogeneic Hematopoietic Stem Cell Transplantation by Vitamin D.
Flamann C; Peter K; Kreutz M; Bruns H
Front Immunol; 2019; 10():2586. PubMed ID: 31749811
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulation and pharmacological strategies in the treatment of graft-versus-host disease.
Li M; Sun K; Welniak LA; Murphy WJ
Expert Opin Pharmacother; 2008 Sep; 9(13):2305-16. PubMed ID: 18710355
[TBL] [Abstract][Full Text] [Related]
14. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
16. Acute graft-vs-host disease: pathobiology and management.
Goker H; Haznedaroglu IC; Chao NJ
Exp Hematol; 2001 Mar; 29(3):259-77. PubMed ID: 11274753
[TBL] [Abstract][Full Text] [Related]
17. Harnessing dendritic cells to improve allogeneic hematopoietic cell transplantation outcome.
Hashimoto D; Merad M
Semin Immunol; 2011 Feb; 23(1):50-7. PubMed ID: 21316261
[TBL] [Abstract][Full Text] [Related]
18. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
Foss FM
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
[TBL] [Abstract][Full Text] [Related]
19. Microbiome: An Emerging New Frontier in Graft-Versus-Host Disease.
Kumari R; Palaniyandi S; Hildebrandt GC
Dig Dis Sci; 2019 Mar; 64(3):669-677. PubMed ID: 30523482
[TBL] [Abstract][Full Text] [Related]
20. New strategies for prevention and treatment of graft-versus-host disease and for induction of graft-versus-leukemia effects.
Deeg HJ
Int J Hematol; 2003 Jan; 77(1):15-21. PubMed ID: 12568295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]